@article{ATM18177,
author = {Michel Farnier},
title = {Lowering low-density lipoprotein cholesterol by PCSK9 inhibition in patients with diabetes on insulin therapy: is it efficacious and safe?},
journal = {Annals of Translational Medicine},
volume = {6},
number = {3},
year = {2018},
keywords = {},
abstract = {Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of the excess morbidity and mortality for individuals with diabetes (1). Patients with type 2 diabetes have an atherogenic lipid profile characterized by elevated non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (apoB) and triglycerides (TG), along with low HDLcholesterol.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/18177}
}